M. Wahba
Princeton University
8 Papers
41 Citations
M. Wahba is an academic researcher from Princeton University. The author has contributed to research in topics: Trifluridine & Tipiracil. The author has an hindex of 4, co-authored 8 publications.
Chat about Author
Papers
Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.
TL;DR: Primary results of RECOURSE demonstrated a significant improvement in overall survival (OS) and progression-free survival (PFS) with TAS-102 vs placebo (PBO).
14
Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer.
Atsushi Ohtsu,Takayuki Yoshino,Alfredo Falcone,Rocio Garcia-Carbonero,Guillem Argiles,Alberto Sobrero,Marc Peeters,Lukas Makris,Fabio Benedetti,Alberto Zaniboni,Yasuhiro Shimada,Kentaro Yamazaki,Yoshito Komatsu,Howard S. Hochster,Heinz-Josef Lenz,Ben Tran,M. Wahba,Kenichiro Yoshida,Eric Van Cutsem,Robert J. Mayer +19 more
TL;DR: TAS-102 is comprised of an antineoplastic thymidine-based nucleoside analog, trifluridine (FTD), and aThymidine phosphorylase inhibitor, tipiracil, and primary results of the RECOURSE ...
10
Supportive treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer.
Robert J. Mayer,Eric Van Cutsem,Takayuki Yoshino,Alfredo Falcone,Rocio Garcia-Carbonero,Guillem Argiles,Alessandro Pastorino,Marc Peeters,Robert Winkler,M. Wahba,Lukas Makris,Alberto Zaniboni,Yasuhiro Shimada,Kentaro Yamazaki,Yoshito Komatsu,Howard S. Hochster,Heinz-Josef Lenz,Ben Tran,Atsushi Ohtsu +18 more
TL;DR: TAS-102 is comprised of an antineoplastic thymidine-based nucleoside analog, trifluridine, and aThymidine phosphorylase inhibitor, tipiracil, andfficacy and safety are confirmed.
6
2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC)
Eiji Shinozaki,Stéphanie Laurent,Cristina Grávalos,Martín Benavides,F. Longo Muñoz,Hirokazu Mizuguchi,M. Wahba,M. Ychou,Fortunato Ciardiello,Salvatore Siena,Kensei Yamaguchi,Kei Muro,Tadamichi Denda,Yasushi Tsuji,Patrick J. Loehrer,H. J. Lenz,Niall C. Tebbutt,Robert J. Mayer,E. Van Cutsem,A. Ohtsu +19 more
5
2150 Low rates of hospitalizations with TAS-102 in the European (EU) subregion of the Phase 3 RECOURSE trial in patients (pts) with metastatic colorectal cancer (mCRC)
Alfredo Falcone,Rocio Garcia-Carbonero,J. Tabernero,Alberto Sobrero,Monika Peeters,Alberto Zaniboni,Howard S. Hochster,H. J. Lenz,Ben Tran,Kensei Yamaguchi,Kei Muro,Tadamichi Denda,Yasushi Tsuji,M. Wahba,Fabio Benedetti,A. Ohtsu,Robert J. Mayer,E. Van Cutsem +17 more
3